Amphastar Pharmaceuticals/$AMPH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
- Ticker
- $AMPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,976
- Headquarters
- Rancho Cucamonga, United States
- Website
- www.amphastar.com
AMPH Metrics
BasicAdvanced
$1.1B
16.02
$1.69
0.91
-
Price and volume
Market cap
$1.1B
Beta
0.91
52-week high
$29.52
52-week low
$16.65
Average daily volume
447K
Financial strength
Current ratio
2.397
Quick ratio
1.663
Long term debt to equity
0.881
Total debt to equity
0.896
Interest coverage (TTM)
5.22%
Profitability
EBITDA (TTM)
194.514
Gross margin (TTM)
47.68%
Net profit margin (TTM)
10.76%
Operating margin (TTM)
18.82%
Effective tax rate (TTM)
23.01%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.11%
Return on equity (TTM)
10.30%
Valuation
Price to earnings (TTM)
16.023
Price to revenue (TTM)
1.679
Price to book
1.5
Price to tangible book (TTM)
9.55
Price to free cash flow (TTM)
8.015
Free cash flow yield (TTM)
12.48%
Free cash flow per share (TTM)
3.372
Growth
Revenue change (TTM)
1.02%
Earnings per share change (TTM)
-37.04%
3-year revenue growth (CAGR)
10.51%
10-year revenue growth (CAGR)
10.53%
3-year earnings per share growth (CAGR)
-4.56%
10-year earnings per share growth (CAGR)
18.52%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
Analyst projections of the future price of Amphastar Pharmaceuticals stock.
Bulls say / Bears say
Second-quarter revenue grew 5%, while gross margin rose to 50.8% from 49.6%. Recent launches, including ipratropium, teriparatide and iron sucrose, helped lift gross profit and broaden the sales base. (SEC)
BAQSIMI prescriptions grew 17% in the second quarter, and sales reached $178.3 million in its third contract year. Management sees peak sales of $250 million to $275 million, although that target depends on sustaining growth and improving pricing. (SEC, Investing.com)
Management expects mid-to-high single-digit revenue growth in 2026 and faster growth in 2027, with insulin aspart and a generic GLP-1 among the anticipated drivers. Successful launches would add growth beyond the existing portfolio, but remain subject to development and regulatory execution. (Investing.com)
The FDA issued a warning letter over manufacturing practices at IMS, citing deficiencies in investigations, environmental monitoring and equipment. Amphastar expects remediation to add $2 million to $3 million in quarterly costs and slow IMS sales; further regulatory action remains possible if the issues are not resolved. (SEC, SEC)
Pricing and competition are weakening important products: second-quarter BAQSIMI sales fell 3% as its average selling price declined, while glucagon sales dropped 42% amid competition and a shift to ready-to-use alternatives. This could offset gains from newer launches. (SEC)
First-half revenue increased by about 3%, but operating income fell roughly 33% and net income fell about 35% year on year. Rising operating expenses mean sales growth has not yet translated into stronger reported earnings. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
AMPH News
AllArticlesVideos
Funds containing AMPH
Fund name | Fund size | $AMPH weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.05% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.05% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.